Leone, Gianmarco;
Orlando, Francesco;
Dutey-Magni, Peter;
Vainauskas, Osvaldas;
Grist, Emily;
Ciani, Yari;
Lall, Sharanpreet;
... the STAMPEDE collaborators; + view all
(2025)
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer:
the STAMPEDE Phase 3 Randomized Clinical Trial.
JAMA Oncology
10.1001/jamaoncol.2024.7051.
(In press).
Preview |
Text
Jama_pre_edited.pdf - Accepted Version Download (7MB) | Preview |
Abstract
We previously reported that abiraterone acetate and prednisolone (hereafter abiraterone) added at initiation of androgen deprivation therapy (ADT) improved survival of metastatic and very high-risk locally advanced prostate cancer and that combining with enzalutamide did not change efficacy.1 Using next-generation sequencing on plasma DNA, we previously showed that genomic alterations of the androgen receptor (AR) gene contribute to resistance to abiraterone or enzalutamide when initiated for metastatic castration-resistant prostate cancer after progression with ADT alone.2 It is unknown whether hormone intensification at start of ADT alters selection of AR alterations within the gene body and/or enhancer region.3
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
